The Cancer Genome Atlas consortium has reported that up to 50% of patients with HGSOC harbor genetic lesions that confer HR deficiencies including BRCA1/2 mutations, BRCA1 methylation, or gene alterations in EMSY, phosphatase and tensin homolog (PTEN), ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), RAD51, or Fanconi-anemia-related gene (sometimes referred to as ‘BRCAness’) [10,11]. This evidence concerns the gene ATM and cancer.